INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
SKIN
SUSTAINABILITY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
MEDIA PACK
CONTRIBUTE
Subscribe
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
SKIN
SUSTAINABILITY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
MEDIA PACK
CONTRIBUTE
SEARCH
SEARCH
advanced search
INTERVIEW
INTERVIEW
Patrick Alexandre
PATRICK ALEXANDRE, CROSSJECT
Shortly after Crossject’s successful IPO on the French NYSE Euronext Paris Exchange (Paris Bourse), Patrick Alexandre spoke about Crossject, its technology and strategy for the future as a publically traded company.
Prev
1
…
4
5
6
Top
